A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of 14C-OSI-906 in Subjects With Advanced Solid Tumors With an Optional Treatment Phase
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Linsitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 12 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.